Treating murine inflammatory diseases with an anti-erythrocyte antibody.

Sci Transl Med 2019 Aug;11(506)

Canadian Blood Services Centre for Innovation, Ottawa, Ontario K1G 4J5, Canada.

Treatment of autoimmune and inflammatory diseases typically involves immune suppression. In an opposite strategy, we show that administration of the highly inflammatory erythrocyte-specific antibody Ter119 into mice remodels the monocyte cellular landscape, leading to resolution of inflammatory disease. Ter119 with intact Fc function was unexpectedly therapeutic in the K/BxN serum transfer model of arthritis. Similarly, it rapidly reversed clinical disease progression in collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis and completely corrected CAIA-induced increase in monocyte Fcγ receptor II/III expression. Ter119 dose-dependently induced plasma chemokines CCL2, CCL5, CXCL9, CXCL10, and CCL11 with corresponding alterations in monocyte percentages in the blood and liver within 24 hours. Ter119 attenuated chemokine production from the synovial fluid and prevented the accumulation of inflammatory cells and complement components in the synovium. Ter119 could also accelerate the resolution of hypothermia and pulmonary edema in an acute lung injury model. We conclude that this inflammatory anti-erythrocyte antibody simultaneously triggers a highly efficient anti-inflammatory effect with broad therapeutic potential.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aau8217DOI Listing
August 2019
281 Reads
15.843 Impact Factor

Publication Analysis

Top Keywords

anti-erythrocyte antibody
8
inflammatory diseases
8
inflammatory
6
ter119
5
expression ter119
4
chemokines ccl2
4
ccl2 ccl5
4
plasma chemokines
4
induced plasma
4
ccl5 cxcl9
4
ter119 dose-dependently
4
dose-dependently induced
4
ccl11 corresponding
4
monocyte percentages
4
percentages blood
4
blood liver
4
alterations monocyte
4
corresponding alterations
4
cxcl10 ccl11
4
ii/iii expression
4

Similar Publications